T-cell receptor mimic antibodies to target KRAS G12D in HLA-A*11:01 patients
Official title: A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
Funded at Precision Biotools INC · NIH-11242083 · Data updated 2026-11-12
A new therapy approach uses specialized antibodies to specifically recognize a KRAS G12D cancer mutation in people with the HLA-A*11:01 molecule.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Precision Biotools INC NIH-funded |
| Lab location | 1 site (Branford, United States) |
| Project start | July 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,221,747 |
| NIH project number | 5R44GM149009-04 |
| Project ID | NIH-11242083 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose cancer carries the KRAS G12D mutation and expresses HLA-A*11:01 would be ideal candidates.
✕Less likely to help
Patients without the KRAS G12D mutation or without HLA-A*11:01 expression may not benefit from this approach.
What this research studies
This phase II effort aims to create and validate T cell receptor mimic antibodies that distinguish the KRAS G12D mutation from the normal KRAS version. It builds on Epivolve technology to improve precision and safety, potentially enabling targeted immunotherapy for patients whose cancers carry this mutation. The work focuses on proving the antibodies can bind the mutant peptide presented by HLA-A*11:01 and trigger a desired immune response with minimal off-target effects. If successful, this platform could broaden options for a range of KRAS-mutant cancers and other neoantigen targets in humans.
Why it matters
Potential benefit: Patients with KRAS G12D-mutant tumors could gain more precise and effective immunotherapies with fewer side effects.
How similar studies have gone: Prior work in TCR mimic antibodies and neoantigen targeting has shown promise, with ongoing development in this area.
Where this research is happening
-
Precision Biotools INC
Branford, United States Active
Researchers
- Principal investigator: Passos, Sara T — Precision Biotools INC
- Study coordinator: Passos, Sara T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.